SCHEMBL14014282

SCHEMBL14014282

NC1NC=Cc2cc(C(=O)O)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA6 P23280 2/20 0.35
CA9 Q16790 2/20 0.35
KDM4E B2RXH2 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
CA4 P22748 1/20 0.35
PTGS2 P35354 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
HPSE Q9Y251 1/20 0.35
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1759252 0.72 KDM4E (0.36) MEN1KMT2ACA12CA1CA2
SCHEMBL7009675 0.69 PARP1 (0.42) L3MBTL1MAPTPOLBTSHRKDM1A
SCHEMBL5738395 0.68 TSHR (0.42) CA12CA1CA2CA6CA9
SCHEMBL7562014 0.67 TSHR (0.41) MEN1KMT2ACA12CA1CA2
SCHEMBL18682217 0.67 TSHR (0.50) MEN1KMT2ACA12CA1CA2
SCHEMBL18670700 0.67 TSHR (0.50) MEN1KMT2ACA12CA1CA2
SCHEMBL9123084 0.64 TSHR (0.52) CA12CA1CA2CA6CA9
SCHEMBL3712689 0.63 ALOX5 (0.44) MEN1KMT2ACA12CA1CA2
Hydrochloric Acid SCHEMBL9365820 0.63 TSHR (0.50) CA12CA1CA2CA6CA9
Isophthalic Acid SCHEMBL4882153 0.59 CA12 (0.65) MEN1KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed